HKMPF
Hikma Pharmaceuticals PLC
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
19.07
▼ 3.12 (14.05%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
22.19
Day high
19.07
Day low
19.07
Volume
40
Market cap
—
P/E (TTM)
—
52W range
16.34 – 25.34
Trailing performance
Returnvs SPY
1W
-0.41%
+0.8%
1M
+8.92%
+5.6%
3M
+16.16%
+13.8%
6M
+1.96%
-9.9%
YTD
+5.96%
-6.0%
1Y
-8.92%
-29.0%
3Y
-16.12%
-91.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on HKMPF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.35B | $3.13B | $2.88B | $2.52B | — | +7.1% |
| Operating revenue | $3.35B | $3.13B | $2.88B | $2.52B | — | +7.1% |
| Cost of revenue | $1.91B | $1.71B | $1.49B | $1.28B | — | +11.4% |
| Gross profit | $1.44B | $1.42B | $1.39B | $1.24B | — | +1.8% |
| Research & development | $151.00M | $141.00M | $149.00M | $144.00M | — | +7.1% |
| Selling, general & admin | $566.00M | $568.00M | $544.00M | $615.00M | — | -0.4% |
| Total operating expense | $808.00M | $803.00M | $780.00M | $756.00M | — | +0.6% |
| Operating income | $633.00M | $612.00M | $610.00M | $482.00M | — | +3.4% |
| Net interest income | -$91.00M | -$80.00M | -$80.00M | -$67.00M | — | -13.8% |
| Pre-tax income | $519.00M | $455.00M | $281.00M | $233.00M | — | +14.1% |
| Tax provision | $112.00M | $93.00M | $89.00M | $42.00M | — | +20.4% |
| Net income | $402.00M | $359.00M | $190.00M | $188.00M | — | +12.0% |
| Net income to common | $402.00M | $359.00M | $190.00M | $188.00M | — | +12.0% |
| Basic EPS | 1.82 | 1.62 | 0.86 | 0.84 | — | +12.3% |
| Diluted EPS | 1.81 | — | 0.85 | 0.84 | 1.81 | — |
| EBIT | $607.00M | $530.00M | $354.00M | $292.00M | — | +14.5% |
| EBITDA | $845.00M | $698.00M | $552.00M | $485.00M | — | +21.1% |
| Basic shares | 220.59M | — | 220.86M | 224.00M | 231.00M | — |
| Diluted shares | 222.68M | 223.49M | 222.37M | 225.00M | — | -0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $217.00M | $188.00M | $205.00M | $270.00M | +15.4% |
| Cash & short-term investments | $243.00M | $213.00M | $229.00M | $292.00M | +14.1% |
| Accounts receivable | $997.00M | $896.00M | $789.00M | $777.00M | +11.3% |
| Inventory | $1.11B | $986.00M | $891.00M | $776.00M | +12.2% |
| Total current assets | $2.64B | $2.26B | $2.10B | $2.00B | +16.8% |
| Property, plant & equipment | $1.45B | $1.33B | $1.14B | $1.08B | +9.2% |
| Goodwill & intangibles | $1.17B | $1.16B | $1.10B | $1.12B | +1.2% |
| Total assets | $5.67B | $5.13B | $4.68B | $4.47B | +10.5% |
| Total current liabilities | $1.45B | $1.98B | $1.34B | $1.08B | -26.5% |
| Current debt | $106.00M | $642.00M | $150.00M | $139.00M | -83.5% |
| Long-term debt | $1.45B | $607.00M | $975.00M | $1.07B | +138.1% |
| Total debt | $1.60B | $1.31B | $1.19B | $1.28B | +22.8% |
| Total liabilities | $3.06B | $2.81B | $2.47B | $2.32B | +9.0% |
| Retained earnings | $2.56B | $2.36B | $2.16B | $2.09B | +8.2% |
| Shareholder equity | $2.59B | $2.31B | $2.20B | $2.13B | +12.3% |
| Working capital | $1.19B | $285.00M | $761.00M | $922.00M | +317.5% |
| Net tangible assets | $1.42B | $1.15B | $1.10B | $1.01B | +23.3% |
| Shares issued | 234.72M | 234.72M | 233.91M | 233.07M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $519.00M | $455.00M | $281.00M | $233.00M | — | +14.1% |
| Depreciation & amortisation | $238.00M | $168.00M | $198.00M | $193.00M | — | +41.7% |
| Stock-based compensation | $23.00M | $27.00M | $25.00M | $22.00M | — | -14.8% |
| Change in working capital | -$251.00M | -$135.00M | $80.00M | -$131.00M | — | -85.9% |
| Operating cash flow | $436.00M | $564.00M | $608.00M | $585.00M | — | -22.7% |
| Capital expenditure | -$317.00M | -$235.00M | -$204.00M | -$225.00M | — | -34.9% |
| Investing cash flow | -$388.00M | -$381.00M | -$333.00M | -$607.00M | — | -1.8% |
| Share buybacks | — | — | $0 | -$300.00M | $0 | — |
| Dividends paid | -$185.00M | -$175.00M | -$137.00M | -$125.00M | — | -5.7% |
| Financing cash flow | -$25.00M | -$188.00M | -$337.00M | -$58.00M | — | +86.7% |
| Free cash flow | $119.00M | $329.00M | $404.00M | $360.00M | — | -63.8% |
| End cash position | $217.00M | $188.00M | $205.00M | $270.00M | — | +15.4% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $217.00M | $236.00M | $188.00M | -8.1% |
| Cash & short-term investments | $243.00M | $236.00M | $213.00M | +3.0% |
| Accounts receivable | $997.00M | $1.07B | $896.00M | -6.7% |
| Inventory | $1.11B | — | $986.00M | — |
| Total current assets | $2.64B | — | $2.26B | — |
| Property, plant & equipment | $1.45B | $1.37B | $1.33B | +5.5% |
| Goodwill & intangibles | $1.17B | — | $1.16B | — |
| Total assets | $5.67B | $5.55B | $5.13B | +2.1% |
| Total current liabilities | $1.45B | $2.06B | $1.98B | -29.3% |
| Current debt | $106.00M | — | $642.00M | — |
| Long-term debt | $1.45B | $798.00M | $607.00M | +81.1% |
| Total debt | $1.60B | $1.56B | $1.31B | +3.0% |
| Total liabilities | $3.06B | $3.00B | $2.81B | +2.1% |
| Retained earnings | $2.56B | $2.47B | $2.36B | +3.4% |
| Shareholder equity | $2.59B | $2.54B | $2.31B | +2.2% |
| Working capital | $1.19B | $501.00M | $285.00M | +137.5% |
| Net tangible assets | $1.42B | — | $1.15B | — |
| Shares issued | 234.72M | — | 234.72M | — |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
22.23
-14.22% from price
SMA 20
21.90
+1.31% from price
SMA 50
20.83
+6.54% from price
SMA 100
19.75
-3.46% from price
SMA 200
19.91
+11.43% from price
EMA 12
22.07
-13.60% from price
EMA 26
21.66
-11.98% from price
EMA 50
21.05
-9.42% from price
RSI (14)
75.7
Overbought
MACD (12,26,9)
0.41
Hist -0.04
ATR (14)
0.06
0.26% of price
Realised vol 30D
20.2%
Annualised
Bollinger upper
22.67
20, 2σ
Bollinger lower
21.14
20, 2σ
50 / 200 cross
Golden
20.83 vs 19.91
Trend bias
Above 200
+11.43%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.02
Less volatile than market
Correlation to SPY
-0.01
Largely independent
Realised vol 30D
20.2%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-35.2%
Peak to trough
Max drawdown 5Y
-60.7%
Peak to trough
ATR 14
0.06
0.26% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Citi sees Hikma discount as unwarranted after upgrade to forecasts
Proactive · 12d ago
Hikma boost as broker raises price target
Proactive · 14d ago
Hikma Pharmaceuticals H1 Earnings Call Highlights
MarketBeat · 18d ago
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Proactive · 18d ago
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Proactive · 32d ago
Hikma recovery story still has further to run after recent rally, says Panmure
Proactive · 33d ago
Shares in Generic-Drug Makers Fall After Trump’s Tariff Plan
The Wall Street Journal · 33d ago
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
Proactive · 39d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.